Announcing Axiom: Eliminating drug toxicity, without using animals! Alex Beatson and I founded Axiom a little over over a year ago with the mission of eliminating drug toxicity by replacing traditional experiments, such as animal testing, with AI models. We are excited to

Agents are finally starting to work in biology. We’ve partnered with Anthropic and major biotech vendors - Vizgen, AtlasXOmics, Takara, 10x Genomics - to build a tool that allows scientists to steer their own analysis with natural language. Raw spatial data to publication

Spent three years looking for a team in Biodefense to invest in. But never found one. So we built it ourselves. Valthos builds next-generation biodefense. As AI and biotech rapidly advance, we're approaching near-universal access to tools with the potential to cure humanity or

Valthos builds next-generation biodefense. Of all AI applications, biotechnology has the highest upside and most catastrophic downside. Heroes at the frontlines of biodefense are working every day to protect the world against the worst case. But the pace of biotech is against

And China is dominating another technology class, one that was supposed to have inherent western advantages . Open link to source article https://t.co/lsbKOzzaLr

Yesterday, I spoke to San Franciscans about a potential federal deployment in our city. I said then what I have said since taking office, that keeping San Franciscans safe is my top priority. Late last night, I received a phone call from the President of the United States. I

“There is no innovation without speculation. No electric vehicles, no Covid vaccines, no OpenAI. No Amazon, Tesla, SpaceX or Moderna. No railroads in the 19th century or internet in the 21st. Every one of those started with a bet — sometimes one that seemed absurd at the time.”

Introducing Axis: the first AI model that generates regulatory DNA elements and predicts their function. Gene therapies suffer from poor efficacy, toxicity & specificity. Models like Axis can help overcome such risks. Axis beats Google DeepMind's AlphaGenome at predicting

New essay at @AsimovPress: An exceptionally deep dive into non-animal methods. It answers: - Why preclinical studies on animals so rarely work in humans (90% of drugs tested on animals fail in human trials.) - What several companies, including @RecursionPharma, are building in

The F.D.A. wants to make animal studies “the exception rather than the norm for pre-clinical safety/toxicity testing” over the next 3-5 years. But just how likely is this to happen? Our latest essay, a Deep Dive into non-animal methods by @cogcelia, answers your questions.

I'm always stunned when I read about the policy decisions that led to the primary care doctor shortage. Some of the craziest: * Medical schools refused to expand for 25 years * We capped the funding we give to residencies * We let the AMA decide medicare reimbursement rates

I'm in @TheArgumentMag this morning! Here's my argument: Organized medicine has captured Medicare and since the 1970s, has made it harder and harder for doctors to choose primary care. But quietly, this administration is pushing back and we should all be rooting them on 🧵:

Pure profound love is the greatest blessing in life. Just married mine.

CORRECTION: THE SITE'S BACK UP! GUESS WHO'S BACK, BACK AGAIN

We should be investing far more into AI-driven drug discovery. Every extra unit of compute has the potential to translate directly into more lives saved (and can have exponential returns). That’s the purest expression of what technology is meant to do.

Wise words from Demis, co-founder of Deepmind / AlphaFold. Isomorphic is going to be one of the top 20 biopharma within 5 years. I completely agree that Alphafold is great but we desperately need foundation models for toxicity and exposure. Checkout what Axiom is doing in this

Demis Hassabis says internally, we are working on technologies much more advanced than AlphaFold 3 The next steps go beyond protein folding into full drug discovery: chemistry, compound design, toxicity, and key properties "we need several AlphaFold-like breakthroughs, not just

More on the @_DimensionCap co-led Series D for @Odyssey_Tx, one of the largest oversubscribed private rounds for therapeutics in 2025 (still possible!). Incredible team, technology, pipeline, and translational data. 🚀🚀🚀 https://t.co/vjc3W8PzS5

Excited to announce @_DimensionCap's partnership with @garydglick and the entire @Odyssey_Tx team on an oversubscribed Series D. They are moving ahead to an exciting chapter where the company will translate multiple programs out of a massively productive discovery platform.

in the last 12 months Enveda has 1. entered the clinic w soon to be 3 new molecules 2. followed the science pursuing medicines with decacorn potential whilst altering billions of global lives 3. added Mikael Dolsten, former CSO of Pfizer, to the board 4. become a biotech unicorn

1/ We started as underdogs. Today, we’re scaling a unicorn. Thrilled to share that @EnvedaBio has raised a $150M Series D, bringing our total funding to over $500M. Led by the incredible team at @PremjiInvest and joined by both new and returning believers. 🧵